Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BYSI
BYSI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BYSI News
BeyondSpring to Present New Therapy at AACR Annual Meeting
1d ago
Newsfilter
BeyondSpring Files Annual Report for 2025
5d ago
Newsfilter
BeyondSpring Reports FY 2025 Financial Results
6d ago
seekingalpha
BeyondSpring to Present at IO360° Conference 2026
Feb 09 2026
Newsfilter
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
Dec 23 2025
Benzinga
BeyondSpring Reports Significant Survival Improvement for Plinabulin in Asian NSCLC Patients
Dec 12 2025
Globenewswire
BeyondSpring Reports Plinabulin Asian Trial Data, Survival Extended to 10.8 Months
Dec 12 2025
Newsfilter
BeyondSpring Reports Plinabulin Clinical Data, OS Increased to 15.8 Months
Dec 11 2025
Globenewswire
BeyondSpring Reports Plinabulin Clinical Data, OS Improved to 15.8 Months
Dec 11 2025
Newsfilter
Transcript of BeyondSpring Inc. (BYSI) Annual Shareholders Meeting for 2025
Sep 15 2025
Newsfilter
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
Aug 13 2025
Newsfilter
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
Jun 03 2025
Newsfilter
BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress
May 12 2025
NASDAQ.COM
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
May 12 2025
Newsfilter
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Nov 11 2024
Newsfilter
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Sep 16 2024
Newsfilter
Show More News
